CoChat

Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition

Open access
Ishizawa, Jo, Nakamaru, Kenji, Seki, Takahiko, Tazaki, Koichi, Kojima, Kensuke, Chachad, Dhruv, Zhao, Ran, Heese, Lauren, Ma, Wencai, Ma, Man Chun John, DiNardo, Courtney, Pierce, Sherry, Patel, Keyur P., Tse, Archie, Davis, R. Eric, Rao, Arvind, Andreeff, Michael · 2018 · Cancer Research
Cited by 58

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Early clinical trials using murine double minute 2 (MDM2) inhibitors demonstrated proof-of-concept of p53-induced apoptosis by MDM2 inhibition in cancer cells; however, not all wild-type TP53 tumors are sensitive to MDM2 inhibition. Therefore, more potent inhibitors and biomarkers predictive of tumor sensitivity are needed. The novel MDM2 inhibitor DS-3032b is 10-fold more potent than the first-generation inhibitor nutlin-3a. TP53 mutations were predictive of resistance to DS-3032b, and allele frequencies of TP53 mutations were negatively correlated with sensitivity to DS-3032b. However, sensitivity to DS-3032b of TP53 wild-type tumors varied greatly. We thus used two methods to create predictive gene signatures. First, by comparing sensitivity to MDM2 inhibition with basal mRNA expression profiles in 240 cancer cell lines, a 175-gene signature was defined and validated in patient-derived tumor xenograft models and ex vivo human acute myeloid leukemia (AML) cells. Second, an AML-specific 1,532-gene signature was defined by performing random forest analysis with cross-validation using gene expression profiles of 41 primary AML samples. The combination of TP53 mutation status with the two gene signatures provided the best positive predictive values (81% and 82%, compared with 62% for TP53 mutation status alone). In addition, the top-ranked 50 genes selected from the AML-specific 1,532-gene signature conserved high predictive performance, suggesting that a more feasible size of gene signature can be generated through this method for clinical implementation. Our model is being tested in ongoing clinical trials of MDM2 inhibitors. Significance: This study demonstrates that gene expression profiling combined with TP53 mutational status predicts antitumor effects of MDM2 inhibitors in vitro and in vivo. Cancer Res; 78(10); 2721–31. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-17-0949

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 58

Metadata

Authors
Ishizawa, J., Nakamaru, K., Seki, T., Tazaki, K., Kojima, K., Chachad, D., Zhao, R., Heese, L., Ma, W., Ma, M. C. J., DiNardo, C., Pierce, S., Patel, K. P., Tse, A., Davis, R. E., Rao, A., & Andreeff, M.
Venue
Cancer Research
Published
2018-05-14
Volume
78
Issue
10
Pages
2721-2731
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2793399311
Cited by
58
References
10
FWCI
1.60
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. https://app.cochat.ai/papers/10.1158/0008-5472.can-17-0949
The paper
Ishizawa, J., Nakamaru, K., Seki, T., Tazaki, K., Kojima, K., Chachad, D., Zhao, R., Heese, L., Ma, W., Ma, M. C. J., DiNardo, C., Pierce, S., Patel, K. P., Tse, A., Davis, R. E., Rao, A., & Andreeff, M. (2018). Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Research. https://doi.org/10.1158/0008-5472.can-17-0949

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.